Can Alpha‑Ketoglutarate Lower Biological Age? A Planned Trial in Middle‑Aged Adults (NCT05706389)

Overview

ClinicalTrials.gov lists a planned clinical trial (NCT05706389) that asks a clear question: can supplementation with alpha‑ketoglutarate (AKG)—a compound the body naturally produces—reduce biological‑age biomarkers in middle‑aged adults?

The study is registered, but no results are posted yet. Details available in the public record are limited, so this article focuses on context and what to look for once results appear.

Why it matters

• Interest in extending healthspan is high, but human data for many “longevity” supplements remain sparse.
• Biological age aims to reflect the body’s functional state more closely than calendar age.
• Middle age may be a practical window to test whether supplements can shift aging‑related markers.

What the trial plans to test

• Source: ClinicalTrials.gov (NCT05706389)
• Study type: clinical trial
• Core question: does AKG supplementation lower biological‑age biomarkers in middle‑aged adults?

The public listing provided here does not specify the dose, duration, sample size, design features (e.g., randomization, placebo control, blinding), or the exact biomarker panels. No outcomes are available yet.

Key terms

• Alpha‑ketoglutarate (AKG): a naturally occurring molecule involved in energy and cellular metabolism. It is being studied as a dietary supplement.
• Biological age: an estimate of the body’s functional state, often derived from patterns in blood tests or molecular markers, which may track health risk better than chronological age.
• Biomarkers of aging: measurable signs (for example, DNA‑methylation clocks, blood proteins, or routine lab values) used as early indicators of health trajectories.

What this could mean

If a well‑conducted trial shows meaningful shifts in aging biomarkers with AKG, that would be a signal for further study—not proof of disease risk reduction or longer life. Keep in mind:

• Surrogate markers are not the same as clinical outcomes.
• Biomarkers can vary day‑to‑day with sleep, stress, diet, activity, and lab procedures.
• A statistically significant change may still be too small to matter in real life if it falls within normal test variability.

How to read the results when they appear

1. Design

2. Endpoints

3. Measurement quality

4. Effect size and durability

5. Safety

6. Transparency

• Was the study randomized and placebo‑controlled? Was it blinded?
• How long did supplementation last, and how was adherence tracked? Were lifestyle factors monitored?
• Which biomarker sets were pre‑specified (e.g., DNA‑methylation clocks, blood proteins, metabolites, routine labs)?
• Was there a plan to handle multiple comparisons and reduce false positives?
• Were methods in place to ensure repeatability and control lab‑to‑lab differences?
• Did changes exceed normal within‑person variability and assay error?
• How large were the changes, and do they have practical meaning?
• Did any effects persist after stopping the supplement (if tested)?
• What adverse events, lab abnormalities, or discontinuations occurred?
• Do reported outcomes match the registry entry? Are any post‑hoc analyses labeled as such? Is data access possible?

Limits and uncertainties

• Public details are incomplete (design, dose, duration, sample size, assays), so no assumptions about effect size or likelihood are warranted.
• Results in middle‑aged adults may not apply to younger or older groups.
• Longevity topics are prone to hype; any positive findings should be replicated and, ideally, linked to clinical outcomes over time.

For now

• NCT05706389 is a registered, planned trial evaluating whether AKG can influence biological‑age markers in middle‑aged adults.
• Until results are posted, it is premature to make claims about benefits or risks. Decisions about supplements should be discussed with a clinician.
• When results arrive, focus on design quality, pre‑specified endpoints, effect sizes relative to measurement noise, consistency across biomarker types, and safety.

Bottom line

This trial asks whether supplementing an endogenous metabolite—alpha‑ketoglutarate—can shift biological‑age markers in middle‑aged adults. The answer could inform future research, but it remains unknown until results are available and carefully evaluated.

Disclaimer: This article is for educational purposes only and is not medical advice. For diagnosis or treatment decisions, consult a qualified clinician.

Sources

• Original publication: https://clinicaltrials.gov/study/NCT05706389